Thomas Powles, MD, MBBS, MRCP, discusses the implications of the positive outcome of the phase 3 EV-301 trial of enfortumab vedotin in patients with urothelial cancers.
Thomas Powles, MD, MBBS, MRCP, professor of genitourinary oncology, director of the Bart Cancer Centre, and lead for Solid Tumour Research at Cancer Research UK, discusses the implications of the positive outcome of the phase 3 EV-301 trial (NCT03474107) of enfortumab vedotin (Padcev) in patients with urothelial cancers.
The EV-301 trial investigated the monoclonal antibody enfortumab vedotin as a targeted therapy in patients who had previously received platinum-based chemotherapy and progressed during or after receiving a PD-1 or PD-L1 inhibitor. Investigators found an overall survival (OS) benefit to enfortumab of 12.88 months versus 8.97 months (HR, 0.70; 95% CI, 0.56-0.89; P = .001).
According to Powles, this trial is the third to show a signal of OS in patients with urothelial cancer, following the KEYNOTE-045 trial (NCT02256436) of second-line pembrolizumab (Keytruda) and the JAVELIN Bladder 100 trial (NCT02603432) of maintenance avelumab (Bavencio). Powles anticipates that enfortumab will be a standard-of-care regimen with potential as a second-line treatment, though it is currently approved following chemotherapy and a PD-1/PD-L1 inhibitor.
TRANSCRIPTION:
0:08 | This research is practice changing. We've not had many OS signals in urothelial cancer over the last 40 years. We know chemotherapy is active, but there weren't really randomized trials to show that. We had a survival signal for second-line pembrolizumab. We had a survival signal for maintenance avelumab, but we haven't really had any other survival signals in bladder cancer. So, this is the third time we've achieved that with a new class of drugs in a very heavily-treated population.
And so, I think this is going to make a massive difference. I think it's going to be a standard of care. I think, for me, the standard of care currently is platinum-based chemotherapy and maintenance avelumab and giving [enfortumab] on progression, which would be a second-line agent essentially, so we’ll be reaching toward this very quickly.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More